Patently Biotech has a new writer. My name is Roy Zwahlen and I am the new Intellectual Property manager at BIO. I am an attorney and political science undergraduate and fascinated with intellectual property policy. I am excited about this opportunity to enter the IP blogosphere.
My hope is to provide information about BIO’s IP activities including conferences and amicus briefs. I also hope to reintroduce our IP staff and spotlight our BIO company members. Finally, I plan on featuring guest writers from around the Biotech industry on IP issues.
I am heading to Boston for BIO’s Intellectual Property Counsels Committee Fall Conference and Committee Meeting from Monday October 18th to Wednesday the 20th. I plan on posting summaries of our panel discussions on the following topics:
- Evolving patent-eligibility standards for genes, biomarkers, diagnostics, and cell-based therapies;
- Valuation of IP when selling, licensing, or acquiring biotech patent rights;
- Present and impending changes to the way you practice before the PTO;
- How to defend your patent in an inter partes reexam;
- Whether inequitable conduct reform is close or elusive;
- Inducement, divided infringement, “abstract idea” exceptions, and other things that go “bump” in the dark if you own Biotech method patents;
- Tales from the edge and beyond: accounts of biotech investment in emerging market countries.
Don’t Forget:
Follow us on Twitter @petepatentagent which will display our new blog posts. Alternatively, the blog has a sign up mechanism to notify you by email when a new blog is posted.
